# BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

> **NCT04827719** · PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 38 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** BST-236

## Key facts

- **NCT ID:** NCT04827719
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-01
- **Primary completion:** 2025-01-13
- **Final completion:** 2025-01-13
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827719, "BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04827719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*